[Haemosiderosis bulbi in a patient with myelodysplastic syndrome (MDS RAEB-1)].
نویسندگان
چکیده
Haemosiderosis bulbi is a degenerative condition of the eye bulb caused by the toxic effects of an intracellular accumulation of haemosiderin. Haemosiderin is a product of the decomposition of haemoglobin. The most common and severe damage takes place in the epithelial cells of the eye tissues. Haemosiderosis bulbi is a complication of the long existing haemophthalmus, the intravitreal bleeding, which is neither spontaneously resorbed nor operatively removed. The condition is characterized by the loss of light perception and the reddish colour of the intrabulbar tissues. The cause of the haemophthalmus in our patient is protracted anaemia due to pre-existing myelodysplastic syndrome (MDS RAEB-1).
منابع مشابه
Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
The International Prognostic Scoring System (IPSS) has been widely used to predict the prognosis of patients with myelodysplastic syndrome (MDS). However, IPSS does not always provide a sufficiently precise evaluation of patients to allow the appropriate choice of clinical interventions. Here, we analyzed the expression of Bmi-1, which is required to regulate the self-renewal in CD34+ cells fro...
متن کاملPlasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups
In recent years the plasma proteomes of several different myelodysplastic syndrome (MDS) subgroups have been investigated and compared with those of healthy donors. However, the resulting data do not facilitate a direct and statistical comparison of the changes among the different MDS subgroups that would be useful for the selection and proposal of diagnostic biomarker candidates. The aim of th...
متن کاملAplastic anemia evolving to myelodysplastic syndrome and later to a lymphoproliferative malignancy in a treated case of carcinoma breast: A case report emphasizing the importance of PET-CT in cutaneous T cell lymphoma
Although aplastic anemia (AA) and myelodysplastic syndrome (MDS) are separate entities with different management, distinction between the two can be difficult on morphological basis due to hypocellularity of bone marrow. MDS is one of the serious complications of AA. Karyotyping is definitive in the diagnosis of MDS. Better and robust investigations like 18F-Fluoro-deoxy-Glucose Posi...
متن کاملExpression Analysis of Let-7a miRNA and its Target Gene NRAS in Cytogenetically Normal Family with Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS), is a group of heterogeneous disorders of hematopoietic stem cell colonies which is determined by incomplete hematopoiesis in one or more cell lines. The incidence increases with age and it has less been reported among patients under 50 years of age. The commonest form of MDS is sporadic, and familial occurrence of MDS is rare. Patients with familial MDS are young...
متن کاملTreatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare.
We treated 23 patients with myelodysplastic syndromes (MDS); 2 refractory anemia (RA) with prior therapy, 11 RA with excess of blasts (RAEB), and 10 RAEB in transformation (RAEB-T), with daily oral 45 mg/m2 all-trans retinoic acid (ATRA) in a multiinstitutional prospective study. In two patients with RAEB and one with RAEB-T, a more than 1,000/microL increase of peripheral neutrophil counts was...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Lijecnicki vjesnik
دوره 132 7-8 شماره
صفحات -
تاریخ انتشار 2010